Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/08/2023 | 194.12% | Needham | → $3 | Reiterates | Buy → Buy |
| 09/07/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/07/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 08/04/2023 | 194.12% | Needham | → $3 | Reiterates | Buy → Buy |
| 08/01/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 08/01/2023 | 390.2% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 06/26/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/15/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/12/2023 | 194.12% | Needham | → $3 | Reiterates | Buy → Buy |
| 04/18/2023 | 194.12% | Needham | → $3 | Reiterates | → Buy |
| 03/24/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/23/2023 | 488.24% | HC Wainwright & Co. | $6.5 → $6 | Maintains | Buy |
| 03/08/2023 | 390.2% | Cantor Fitzgerald | → $5 | Reiterates | → Overweight |
| 03/01/2023 | 537.25% | HC Wainwright & Co. | → $6.5 | Reiterates | → Buy |
| 01/25/2023 | 537.25% | HC Wainwright & Co. | $6 → $6.5 | Maintains | Buy |
| 05/12/2022 | 488.24% | HC Wainwright & Co. | $7.5 → $6 | Maintains | Buy |
| 09/22/2021 | 684.31% | Aegis Capital | $9 → $8 | Maintains | Buy |
| 09/22/2021 | — | WBB Securities | Upgrades | Buy → Strong Buy | |
| 03/04/2021 | 782.35% | Aegis Capital | → $9 | Initiates Coverage On | → Buy |
| 08/26/2020 | 390.2% | Citigroup | $6 → $5 | Maintains | Buy |
| 03/05/2020 | 488.24% | Needham | $10 → $6 | Maintains | Buy |
| 12/04/2019 | 512.75% | WBB Securities | → $6.25 | Upgrades | Speculative Buy → Buy |
| 09/04/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 06/06/2019 | 488.24% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 05/17/2019 | 96.08% | Wedbush | $7 → $2 | Downgrades | Outperform → Neutral |
| 03/01/2019 | 586.27% | Wedbush | $12 → $7 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/22/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 09/08/2023 | 194.12% | 李约瑟 | →$3 | 重申 | 购买→购买 |
| 09/07/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 08/07/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | →购买 |
| 08/04/2023 | 194.12% | 李约瑟 | →$3 | 重申 | 购买→购买 |
| 08/01/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | →购买 |
| 08/01/2023 | 390.2% | 康托·菲茨杰拉德 | →$5 | 重申 | 超重→超重 |
| 2023/06/26 | 488.24% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 2023年05月15日 | 488.24% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 2023年05月12日 | 194.12% | 李约瑟 | →$3 | 重申 | 购买→购买 |
| 04/18/2023 | 194.12% | 李约瑟 | →$3 | 重申 | →购买 |
| 03/24/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | →购买 |
| 03/23/2023 | 488.24% | HC Wainwright公司 | $6.5→$6 | 维护 | 买 |
| 03/08/2023 | 390.2% | 康托·菲茨杰拉德 | →$5 | 重申 | →超重 |
| 03/01/2023 | 537.25% | HC Wainwright公司 | →$6.5 | 重申 | →购买 |
| 2023年1月25日 | 537.25% | HC Wainwright公司 | $6→$6.5 | 维护 | 买 |
| 2022年05月12日 | 488.24% | HC Wainwright公司 | $7.5→$6 | 维护 | 买 |
| 09/22/2021 | 684.31% | 宙斯盾资本 | $9→$8 | 维护 | 买 |
| 09/22/2021 | - | WBB证券 | 升级 | 购买→强买 | |
| 03/04/2021 | 782.35% | 宙斯盾资本 | →$9 | 开始承保 | →购买 |
| 2020/08/26 | 390.2% | 花旗集团 | $6→$5 | 维护 | 买 |
| 03/05/2020 | 488.24% | 李约瑟 | $10→$6 | 维护 | 买 |
| 2019/12/04 | 512.75% | WBB证券 | →$6.25 | 升级 | 投机性买入→买入 |
| 2019年09月04日 | - | 韦德布什 | 升级 | 中性→表现优异 | |
| 2019年06月06日 | 488.24% | 奥本海默 | →$6 | 开始承保 | →跑赢大盘 |
| 2019年05月17日 | 96.08% | 韦德布什 | $7→$2 | 评级下调 | 跑赢→中性 |
| 2019年03月01日 | 586.27% | 韦德布什 | $12→$7 | 维护 | 跑赢大盘 |
What is the target price for Cidara Therapeutics (CDTX)?
Cidara Treeutics(CDTX)的目标价格是多少？
The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by HC Wainwright & Co. on September 22, 2023. The analyst firm set a price target for $6.00 expecting CDTX to rise to within 12 months (a possible 488.24% upside). 16 analyst firms have reported ratings in the last year.
西达拉治疗公司(纳斯达克代码：CDTX)的最新目标价是由HC Wainwright&Co.于2023年9月22日报道的。这家分析公司将目标价定为6美元，预计CDTX将在12个月内上涨至(可能上涨488.24%)。过去一年，有16家分析公司公布了评级。
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
Cidara治疗公司(CDTX)的最新分析师评级是多少？
The latest analyst rating for Cidara Therapeutics (NASDAQ: CDTX) was provided by HC Wainwright & Co., and Cidara Therapeutics reiterated their buy rating.
西达拉治疗公司(纳斯达克代码：CDTX)的最新分析师评级由HC Wainwright&Co.提供，西达拉治疗公司重申其买入评级。
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Cidara Treeutics(CDTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Cidara Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Cidara治疗公司的最后一次评级是在2023年9月22日提交的，所以你应该预计下一次评级将在2024年9月22日左右的某个时候提供。
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
分析师对Cidara Treeutics(CDTX)的评级正确吗？
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Cidara Therapeutics (CDTX) is trading at is $1.02, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Cidara治疗公司(CDTX)评级被重申，目标价在0.00美元至6.00美元之间。Cidara Treateutics(CDTX)目前的交易价格为1.02美元，在分析师的预测范围内。